Skip to main content
    C

    Castle Biosciences Inc (CSTL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $32.98
    +0.23 (+0.70%)

    Market Cap: $1.01B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Castle Biosciences Inc (CSTL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Castle Biosciences (CSTL) has a market cap of $1.01B and an enterprise value of $941.39M. Its share count is up 5.37% from a year earlier.

    Total Valuation

    Enterprise value is 6.73% below the market cap, as cash exceeds debt.

    Market Cap$1.01B
    Enterprise Value$941.39M
    Latest price (Nov 17, 2026)$32.98

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.77% in the quarter ended Sep 30, 2026 and grew 4.90% a year over 2 years.

    Shares Outstanding30.63M
    Shares Change (YoY)+5.37%
    Shares Change (QoQ)+0.77%
    Share Count Growth (2Y CAGR)+4.90%

    Valuation Ratios

    Sales and book value multiples are 2.7x and 2.1x. Its year-end P/S ranged from 2.3x to 20.7x from 2019 to 2025.

    P/S Ratio2.7x
    Forward P/S2.6x
    P/B Ratio2.1x
    P/TBV Ratio2.6x
    P/FCF Ratio254.9x
    P/OCF Ratio25.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 237.8x free cash flow.

    EV / Sales2.5x
    EV / FCF237.8x

    Price Statistics

    The stock is down 1.41% over 52 weeks and trades 3.99% below its 50-day average.

    Beta (1Y)1.12
    52-Week Change-1.41%
    1-Month Change+2.53%
    3-Month Change+2.04%
    6-Month Change+71.77%
    5-Year Change-40.40%
    Total Return (1Y)-1.41%
    Total Return (3Y CAGR)+18.86%
    Total Return (5Y CAGR)-7.73%
    Return vs SPY (1Y)-13.26%
    Max Drawdown (1Y)-57.83%
    Max Drawdown (3Y)-57.83%
    Sharpe Ratio (1Y)-0.03
    Correlation with SPY (1Y)0.28
    50-Day Average$34.35
    200-Day Average$28.12
    52-Week Range$17.72 to $44.28
    RSI (14 Days)45.1
    Average Volume (20 Days)452.70K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.28x current liabilities, and total debt is 0.02x shareholder equity.

    Current Ratio5.28x
    Quick Ratio5.12x
    Debt / Equity0.02x
    Debt / FCF2.54x
    Interest Coverage15.03x

    Returns and Efficiency

    Return on invested capital is -5.37% over the last 12 months, against a 5-year average of -7.69%.

    Return on Equity (ROE)-4.81%
    Return on Assets (ROA)-3.97%
    Return on Invested Capital (ROIC)-5.37%
    ROE (5Y Average)-8.05%
    ROA (5Y Average)-7.04%
    ROIC (5Y Average)-7.69%
    Asset Turnover0.66x
    Inventory Turnover8.25x
    Receivables Turnover7.51x
    Cash Conversion Cycle45 days

    Scores

    CSTL has an Altman Z-Score of 6.51, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score6.51
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $377.13M over the last 12 months is up 9.78% from the 12 months before.

    Revenue$377.13M
    Revenue Growth (YoY)+9.78%
    Gross Profit$290.66M
    Operating Income-$28.04M
    Pretax Income-$22.62M
    Net Income-$23.01M
    EBITDA-$12.17M
    Reported EPS (TTM)-$0.77

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 82.57% of the $579.41M in total assets.

    Cash and Equivalents$77.99M
    Total Debt$10.08M
    Net Cash$67.91M
    Net Cash Per Share$2.22
    Working Capital$289.25M
    Shareholder Equity$478.44M
    Book Value Per Share$15.62
    Tangible Book Value$386.95M
    Tangible Book Per Share$12.63
    Total Assets$579.41M
    Total Liabilities$100.96M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $35.78M of capital spending, operating cash flow left $3.96M of free cash flow.

    Operating Cash Flow$39.74M
    Capital Expenditures$35.78M
    Free Cash Flow$3.96M
    FCF Per Share$0.13
    Depreciation and Amortization$17.85M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -7.43%, against a 5-year average of -27.30%.

    Gross Margin77.07%
    Operating Margin-7.43%
    Pretax Margin-6.00%
    Net Margin-6.10%
    EBITDA Margin-3.23%
    FCF Margin1.05%
    Gross Margin (5Y Average)80.12%
    Operating Margin (5Y Average)-27.30%
    Net Margin (5Y Average)-21.98%

    Growth

    Revenue grew 35.94% a year over 3 years.

    Revenue Growth (3Y CAGR)+35.94%
    Revenue Growth (5Y CAGR)+40.60%
    FCF Growth (5Y CAGR)+40.83%
    Book Value Per Share Growth (2Y CAGR)+5.53%
    Tangible Book Per Share Growth (2Y CAGR)+11.99%

    Revenue and profit by year

    Dividends and Yields

    CSTL does not pay a dividend. Its free cash flow yield is 0.39%.

    FCF Yield0.39%
    Buyback Yield-0.36%
    Shareholder Yield-0.36%

    Peer Position

    Against 10 similar companies, CSTL has the 6th highest P/S.

    P/S Ratio2.7x vs 2.9x median
    ROIC-5.37% vs -12.14% median
    Revenue Growth (Trailing 4 Quarters, YoY)+9.78% vs +13.98% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 12.29% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+12.29%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CSTL

    What is CSTL's market cap?

    Castle Biosciences has a market cap of $1.01B. Its enterprise value, which adds debt and subtracts cash, is $941.39M.

    How many shares of CSTL are outstanding?

    Castle Biosciences has 30.63M shares outstanding. The count is up 5.37% from a year earlier.

    Does CSTL pay a dividend?

    No. Castle Biosciences does not pay a dividend.

    How much debt does CSTL have?

    Castle Biosciences has $10.08M of total debt and $77.99M of cash and equivalents, a net cash position of $67.91M.